Results 11 to 20 of about 9,189 (185)
Antibiotics, 2021 β-lactam–avibactam combinations have been proposed as carbapenem-sparing therapies, but little data exist on their in vitro activities in infections with high bacterial inocula.
Moonsuk Bae, Taeeun Kim, Joung Ha Park
exaly +4 more sources
The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases [PDF]
Antibiotics, 2021 Infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales and Pseudomonas are increasingly reported worldwide and are usually associated with high mortality rates (>30%).
Carola Mauri +2 more
exaly +6 more sources
MSystems, 2020 Aztreonam-avibactam is a promising antimicrobial combination against multidrug-resistant organisms, such as carbapenemase-producing Enterobacterales. Resistance to aztreonam-avibactam has been found, but the resistance mechanism remains poorly studied ...
Yu Feng, Alan Mcnally, Zhiyong Zong
exaly +4 more sources
Antibiotics, 2023 Background: Despite the availability of new options (ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol), it is still very difficult to treat infections caused by metallo-β-lactamase (MBLs)-producers resistant to aztreonam.
Cécile Emeraud +2 more
doaj +2 more sources
Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools [PDF]
Frontiers in Microbiology, 2023 IntroductionAntimicrobial resistance is a growing problem that necessitates the development of new therapeutic options. Cefiderocol and aztreonam (AT) are often the last active β-lactams for treating metallo-β-lactamases (MBL)-producing Gram-negative bacilli.
Gil Verschelden +12 more
core +8 more sources
Rapid Aztreonam/Avibactam NP test for detection of aztreonam/avibactam susceptibility/resistance in Enterobacterales. [PDF]
J Clin Microbiol, 2023 ABSTRACT Aztreonam-avibactam (AZA), a newly developed β-lactam/β-lactamase inhibitor combination , is a treatment option for infections due to carbapenem-resistant Enterobacterales (CRE), including metallo-ß-lactamase producers, regardless of additional production of broad-spectrum serine-ß-lactamases ...
Viguier C +5 more
europepmc +4 more sources
Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing Enterobacterales [PDF]
Journal of Antimicrobial Chemotherapy, 2021 Abstract Background Aztreonam/avibactam is being developed for its broad activity against carbapenemase-producing Enterobacterales, including those with metallo-β-lactamases (MBLs). Its potential to select resistance in target pathogens was explored.
Mushtaq, Shazad +4 more
openaire +5 more sources
Microbiology Spectrum, 2021 Aztreonam-avibactam is under clinical development for multidrug-resistant Gram-negative infections. We evaluated in vitro activity against 341 recent clinical isolates.
David R. Snydman, Laura McDermott
doaj +3 more sources
Resistance to aztreonam-avibactam due to a mutation of SHV-12 in Enterobacter
Annals of Clinical Microbiology and Antimicrobials, 2023 Aztreonam-avibactam is an important option against Enterobacterales producing metallo-β-lactamases (MBLs). We obtained an aztreonam-avibactam-resistant mutant of an MBL-producing Enterobacter mori strain by induced mutagenesis. Genome sequencing revealed
Shikai Wu, Ke Ma, Yu Feng, Zhiyong Zong
doaj +3 more sources
Journal of Global Antimicrobial Resistance, 2021 Objectives: While aztreonam-avibactam is a potent β-lactam-β-lactamase-inhibitor combination, reduced in vitro activity against some Enterobacterales isolates has been reported. In this study, globally collected clinical isolates of Enterobacterales with
Krystyna M Kaźmierczak +2 more
exaly +3 more sources